Genmab — August 2018
-
F L - are you referring to the Immatics deal? The enourmous milestones they have to pay, are only due if the studies are successful. They are paid in trances gradually when the different studies progesses and shows success. I would therefore see it as a success if they end up paying Immatics the entire amount. Because then they will have some new products on the market.
-
JV.... Vedr. din kommentar 10:30. Der skriver du at David og Jan har solgt ud af deres beholdning igennem de seneste par år.... Jeg har da også lagt mærke til at de hver især har solgt (lidt) ud, i forhold til deres beholdninger. Og troede egentlig at de solgte for at finansiere nye warrrants... - Har jeg misforstået noget her?
-
David sælger for det meste alt, hvad han bliver tildelt, Jan er lidt mere tilbageholdende
-
Raun - David sælger konsekvent alle aktier han får gennem warrent exercise. David tager ingen risiko på Genmab gennem aktiebeholdning
-
OK, sā David har i forhold til de warrents han har exerciset gennem tiderne en mikroskopisk risiko på Genmab aktier
-
GeorgeBest, I was also talking about the larger organization he is setting up. Hiring a lot people, doing a lot more themselves. So they do become more reliant on success of those and other deals. Wouldn't smaller investments be better so cash can be preserved and paid out? If investments don't succeed, we've burnt away a decent amount of Dara's cashflow and give up stock upside
. -
Tak Stockbull. Det var faktisk en interessant oplysning.
-
F L - we as minority shareholders can‘t do anything about the strategy. We can discuss it to the end of out days, It won‘t change. It is certainly a more risky strategy than just outlicening everything early on. But Jan van de Winkel has chosen this strategy, there are some like Jørgen Varnæs who don‘t agree with him. If TV, AXL and DR5 all are succesful and reach the marked, then his strategy was right, and everybody will clap their hands. Genmab will be entitelt to keep most of the profits
-
themselves instead of 12-20% as with Darzalex and Arzerra. He has decided. We have to follow or quit....
-
Netop GB.
-
aaaarh - hæng nu lige på. Dara dealen giver 12-20% af omsætningen. Det er en helt anden fisk end 12-20% af profits
-
og så glæder jeg mig til at blive overbevist om, at GEN kan køre disse studier på en meget større skala, så man ikke bliver flaskehals for sig selv.
-
men jeg kan godt forstå, at I tænker at en omfattende strategi, hvor GEN selv vil bringe omfattende programmer til markedet er kortsigtet
-
Altså vi har en forward p/e for 2019 på 27-28 stykker lige nu. Og det er selvom Dara næste år er langt fra peaksale.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind